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TECHNICAL ADVANCE
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A new efficient method to detect genetic
interactions for lung cancer GWAS
Jennifer Luyapan1,2, Xuemei Ji2, Siting Li1,2, Xiangjun Xiao3, Dakai Zhu2,3, Eric J. Duell4, David C. Christiani5,6,
Matthew B. Schabath7, Susanne M. Arnold8, Shanbeh Zienolddiny9, Hans Brunnström10, Olle Melander11,
Mark D. Thornquist12, Todd A. MacKenzie1,2, Christopher I. Amos1,2,3* and Jiang Gui1,2*

Abstract
Background: Genome-wide association studies (GWAS) have proven successful in predicting genetic risk of disease
using single-locus models; however, identifying single nucleotide polymorphism (SNP) interactions at the genomewide scale is limited due to computational and statistical challenges. We addressed the computational burden
encountered when detecting SNP interactions for survival analysis, such as age of disease-onset. To confront this
problem, we developed a novel algorithm, called the Efficient Survival Multifactor Dimensionality Reduction (ES-MDR)
method, which used Martingale Residuals as the outcome parameter to estimate survival outcomes, and implemented the Quantitative Multifactor Dimensionality Reduction method to identify significant interactions associated
with age of disease-onset.
Methods: To demonstrate efficacy, we evaluated this method on two simulation data sets to estimate the type I
error rate and power. Simulations showed that ES-MDR identified interactions using less computational workload
and allowed for adjustment of covariates. We applied ES-MDR on the OncoArray-TRICL Consortium data with 14,935
cases and 12,787 controls for lung cancer (SNPs = 108,254) to search over all two-way interactions to identify genetic
interactions associated with lung cancer age-of-onset. We tested the best model in an independent data set from the
OncoArray-TRICL data.
Results: Our experiment on the OncoArray-TRICL data identified many one-way and two-way models with a singlebase deletion in the noncoding region of BRCA1 (HR 1.24, P = 3.15 × 10–15), as the top marker to predict age of lung
cancer onset.
Conclusions: From the results of our extensive simulations and analysis of a large GWAS study, we demonstrated
that our method is an efficient algorithm that identified genetic interactions to include in our models to predict
survival outcomes.
Keywords: Genetic interactions, Machine learning, Genome-wide association study, Lung cancer
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Background
A fundamental aim of studying human genetics is to predict disease risk from genomic data. Genome-wide association studies (GWAS) that used single-locus models by
testing each single nucleotide polymorphism (SNP) for
association with a phenotype, proved to be instrumental in identifying thousands of genetic variants associated with human traits and disorders [1–4]. However,

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Luyapan et al. BMC Med Genomics

(2020) 13:162

most of the findings explained only a small proportion
of the genetic effects on diseases and traits [1, 5]. The
complex biological mechanisms and genetic architectures of diseases motivated researchers to not only study
main additive effects of single genetic variations, but also
interactions between multiple variants with non-additive
effects to explain more of the heritability of complex diseases [6–10]. As the availability of large genome-wide
genotype and next generation sequencing data continues
to grow, detecting genetic interactions (i.e., SNP interactions) will become more feasible with increasing power
to detect significant associations [11]. At the same time,
epistasis detection faces computational and statistical
challenges in analyzing high-dimensional data and in
testing millions of interaction models from an exhaustive
search in GWAS [6, 12]. The number of tests increases
exponentially when analyzing higher orders of interactions, which require immense computing resources and
processing time. Additionally, if the genotypic combinations that confer risk are nonadditive, finding the combinations of genotypes that increase risk can become a
complex combinatorial challenge [7].
With the arrival of multi-dimensional and complicated genetic data sets, researchers have adapted to this
growth by integrating machine learning methods to analyze complex genetic architectures. In genetic epidemiology, a popular series of methods were centered around
a machine learning approach adapted to detect gene–
gene interactions called the Multifactor Dimensionality
Reduction (MDR) method. First introduced by Ritchie
et al. (2001), MDR aimed at reducing high-dimensional
genetic interacting loci to a one-dimensional binary
variable that could be easily classified into high and low
risk groups [7]. While MDR have successfully facilitated
detection and characterization of multiple genetic loci,
there were disadvantages to this algorithm that limited
its use on diverse data structures such as survival data,
which is often a primary outcome of interest in cancer
research. Gui et al. [13, 14] have expanded on the MDR
algorithm to different phenotypes, survival and continuous outcomes data. Survival MDR (Surv-MDR) extended
the analysis of dichotomous traits in MDR to censored
and time-to-event survival data using a log-rank test to
classify sets of multi-loci combinations. This algorithm
demonstrated proficiency in identifying genetic interactions associated with censored time-to-death or timeto-event data; however, it was more computationally
demanding than MDR and it did not allow for covariate
adjustments important for controlling confounding factors [13]. Quantitative MDR (QMDR) offered a computationally efficient algorithm to identify genetic interactions
associated with a quantitative outcome, but it also did
not allow for covariate adjustments such as age, gender,
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environmental toxins, and other confounding factors to
accurately identify genetic association relations [14].
Currently, there are limited methods capable of identifying genome-wide genetic interactions efficiently
with adjustment for covariates when studying age of
disease-onset, such as a patient’s age at first diagnosis
or recurrence of disease, for large-scale studies due to
computational demands. It is important to have reliable
estimates on the age of first diagnosis to understand the
etiology of the disease and to tailor clinical practices,
especially when determining the appropriate starting
age for diagnostic screening, such as lung cancer screening [15]. In this study, we demonstrated how the Efficient
Survival Multifactor Dimensionality Reduction (ESMDR) method improved on the efficiency of Surv-MDR
and allowed for adjustment of covariate effects to analyze large-scale survival and genetic data to analyze age
of disease-onset in association with SNP interactions.
Our method used Martingale Residuals as the estimated
survival outcome with adjustment for confounding factors that provided an efficient and effective identification
of genetic interactions associated with survival outcomes. We demonstrated the strength of the proposed
method by designing two simulations to evaluate the
5% type I error threshold through an evaluation of the
empirical null distribution and to analyze the predictive
power of ES-MDR. To analyze the effectiveness of the
ES-MDR method, we evaluated our approach using the
genome-wide genotyped lung cancer OncoArray-TRICL
(Transdisciplinary Research Into Cancer of the Lung)
Consortium data to detect and characterize SNP interactions that were associated with lung cancer age-of-onset.

Methods
In this section, we discuss how we improved the computational efficiency without reducing accuracy to develop
the ES-MDR method when analyzing SNP interactions
(i.e., joint effects of two SNPs) in association with age of
disease-onset.
Incorporating martingale residuals for age‑of‑onset
survival analysis

ES-MDR improved the efficiency of Surv-MDR and
applied the QMDR algorithm to analyze age of disease-onset in association with genetic interactions.
Our novel ES-MDR approach used a combination of
survival analysis and QMDR for continuous outcome
analysis in two steps. In the first step, we started replacing event time and status with Martingale Residuals
with covariate adjustment as a new continuous score.
In the second step, we applied QMDR to efficiently categorize the genotype combinations into high-risk and
low-risk groups. The best model was determined in the
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same way as QMDR, by using the cross-validated t-test
statistic computed from a continuous variable attribute
(e.g., Martingale Residuals) to determine the best interaction and overall model.
The novel algorithm for ES-MDR was performed as
follows:
1 Selected K SNPs from all the SNPs in the data set and
created a contingency table among every genotype
combination of K SNPs.
2 For each multi-locus genotype combination cell,
summed the Martingale Residuals between samples
with and without each genotype combination.
3 Labeled cells “high-risk” if the sum of the Martingale
Residuals was positive; otherwise negative Martingale Residuals were labeled “low-risk”.
4 Pooled all the high-risk labeled cells into one group
and all the low-risk labeled cells into another group
to create a new one-dimensional variable.
Using Martingale Residuals to determine high or low
risk group for survival data analysis was comparable to
using the log-rank test statistic in Surv-MDR, however,
more efficiently when classifying genotype combinations. It can be shown that the sum of the Martingale
Residuals is a good surrogate variable of the log-rank
test statistics for the purpose of determining high/low
risk groups for each genotype combination. Next, we
compared the similarities of the equations for Martingale Residuals and the log-rank test statistic. The
sign and magnitude of the Martingale Residuals were
dependent on the association of SNPs and the hazard
function in the following equation:

In this equation, δi(t) denotes the number of observed
events that occur at each survival time t. The number of
expected events was calculated using the cox-proportional hazards model with x as the genetic factor and y
as the adjusted covariate. The log-rank test statistic was
defined as the following:

J 
j=1
O1j − E1j

C=
J
j=1
Vj
Here, we show that Martingale Residuals is equivalent
to the numerator of the log-rank test statistic. Therefore, the sum of the Martingale Residuals is equal to
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the log-rank test statistic when the variance is set to 1.
This infers that using Martingale Residuals as a substitute for the log-rank test statistic in evaluating genomic
combinations associated with survival outcomes could
provide the same data reduction and categorization
process as Surv-MDR.
Evaluation through simulations

Our purpose of running a simulation study was to evaluate how well ES-MDR performed and how well it performed compared with Surv-MDR. To demonstrate the
strength of the proposed method, two simulations were
designed to evaluate the testing score’s null distribution
to evaluate the type I error rate and to analyze power.
Simulation I

The first simulation study was created to estimate the
5% type I error threshold by evaluating an empirical null
distribution with independent non-interacting SNPs and
quantitative outcome values. Here, we created sets of
SNPs (m = 10, 20, 50) with additive coding and sample
sizes (n = {200, 400, 800, 1600}) in the simulation data.
For every combination of m and n, we simulated m SNPs
with minor allele frequencies (MAF) drawn from the uniform distribution over the interval U (0.1, 0.5). Then we
simulated n continuous outcomes from a standard normal distribution. The SNP and continuous outcome data
were created independently to ensure that there were
no associations between SNPs and the outcome. These
steps were repeated to create 1000 null data sets for 24
different groups varied by the number of SNPs, sample
size, and MAF. As a result, a total of 24,000 data sets
were generated. Simulations were conducted in R 3.0.0
(Vienna, Austria). To determine whether the type I error
rate was close to 5%, we analyzed the percentage of times
that ES-MDR randomly identified two interacting SNPs
from a null data set.
Simulation II

The second simulation study was created to evaluate the
power of ES-MDR with a data set that included quantitative outcome variables and a pair of functional interacting SNPs and 18 non-interacting SNPs. Surv-MDR was
performed to evaluate whether ES-MDR was as effective
as Surv-MDR in identifying functional SNPs.
The simulation data sets included different penetrance
functions that described the probabilistic relationship
between the quantitative outcome variable and functional
SNPs generated with additive coding. We considered two
different MAFs (0.2 and 0.4) and seven different broadsense heritability statistics (0.01, 0.02, 0.05, 0.1, 0.2, 0.3,
and 0.4) to create a total of 14 unique model combinations, where the two functional SNPs associated with the
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outcome were evenly distributed across the seven heritability statistics. To create a purely epistatic model, each
of the 14 unique models had one or the other functional
SNP (MAF 0.2 or 0.4) with no main effects. The 14 alleleheritability frequency combinations were replicated five
times to generate 70 models with varying sample sizes
that included size (n) = {400, 800, 1600}.
Assuming SNP1 and SNP2 were the two functional
SNPs. Let fij be an element from the ith row and jth column of a penetrance function. We generated the binary
variable from a Bernoulli distribution with the following:


P high risk|SNP1 = i, SNP2 = j = fij
We randomly selected 200 high-risk subjects and 200
low-risk subjects from each of the 70 probabilistic models to create one simulated data set. We repeated this
simulation 100 times to obtain at total of 7,000 data sets.
To generate the survival time, we used the Cox-proportional hazards (Cox ph) model:

h(t|x) = h0 (t) exp (βx)
In this equation, h
 0(t) is the baseline hazard function
with a Weibull distribution using the shape parameter of
5 and the scale parameter of 2. The x is the genetic factor fixed at value 1 for high risk patients and 0 for low
risk patients. ß represents the effect size or the log hazard ratio for a one-unit increase in x (all other covariates
held constant). The censoring fractions were sampled
from the uniform distribution over the interval U (0,4)
from the Bernoulli distribution, resulting in 40% censoring. Finally, we merged survival time and censoring status
with the SNP data.
We used Martingale Residuals in our novel ES-MDR
method to classify each multi-locus genotype combination into high-risk and low-risk groups. The Martingale
Residual is the stochastic component and in residual
form gives the following:

M(t|x) = δ(t) − h0 (t) exp (βx)
In this example, δ(t) denotes the number of expected
events that occurred at each survival time t. Assuming a
null model with no target effects (ß = 0), this residual is
the difference between the observed events and expected
number of events. The sign and magnitude of the Martingale Residuals are dependent on the association of SNPs
and the hazard rate function. Each individual genotype
with a positive Martingale Residual (i.e., greater than or
equal to 0) was classified as high-risk. Otherwise, a negative Martingale Residual was classified as low-risk. For
every multi-locus genotype combination of SNPs, we
computed the sum of the Martingale Residuals to obtain
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a new variable that could be used to classify into the
high-risk or low-risk group.
To estimate the power of the proposed method, we ran
ES-MDR on each of the 7000 data sets and searched for
the best model over all possible one- (i.e., single-locus),
two- (i.e., two interacting loci), and three-way (i.e., three
interacting loci) interaction models, using the T-statistic testing score. We also used the 95th percentile of
the testing score from the null models as a threshold to
guard against any non-significant findings. The power
was estimated as the percentage of time ES-MDR correctly included the two functional interacting SNPs in
the best model out of each set of 7000 data sets. This
significant threshold for the results was at the 0.05 level.
For comparison, we ran Surv-MDR on the simulated data
to define its power. Training and testing scores for ESMDR were analyzed using two-fold cross-validation. The
rational for using two-fold cross-validation [16] was that
there would be no overlap between training sets and that
all the predicted values were independent of each other.
The best model was selected with the smallest prediction
error and largest consistency in including the two functional interacting SNPs.
OncoArray‑TRICL genotyping and quality control

A total of 533,631 SNPs from 57,775 individuals in
the OncoArray-TRICL Consortium population-based
study, selected from 29 studies across North America
and Europe, as well as Asia, were genotyped using the
Illumina OncoArray-500K BeadChip Platform, which
included the genome-wide backbone and select loci
known to be associated with cancer phenotypes. To
facilitate efficient genotyping and minimize variability
that might arise from genotyping at multiple sites, genotyping was conducted at the following five institutions:
the Center for Inherited Disease Research, the Beijing
Genome Institute, the Helmholtz Zentrum München,
Copenhagen University Hospital, and the University of
Cambridge. Quality control steps described previously
were followed for this OncoArray-TRICL data set [17].
The following participants were excluded from the current study: participants who lacked lung cancer status
(did not participate in the lung cancer studies), smoking
status, and age and gender information at diagnosis, participants who were close relatives (second degree relatives or closer), duplicate individuals, with non-European
ancestry, with low-quality extracted DNA, with low callrate for genotype data, and participants who did not pass
other quality control measures. As a result, a total of
14,935 lung cancer cases and 12,787 controls remained in
the current study. We restricted SNP filtering to a minimum to include more SNPs for analysis. We included
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SNPs with MAF ≥ 0.01 and SNPs with 50% and above
genotyping rate.
OncoArray‑TRICL data analysis

We applied ES-MDR to the OncoArray-TRICL Consortium population-based study to identify genetic interactions in association with lung cancer age-of-onset. The
OncoArray-TRICL Consortium is a collaboration among
world leaders to investigate common causes of cancer
susceptibility and progression [17]. Lung cancer cases
and controls were genotyped using the OncoArray genotyping array known to tag cancer traits and susceptibility
loci in addition to the GWAS backbone; this array consisted of approximately 533,000 tagged SNPs. We identified 27,722 participants (14,935 lung cancer cases and
12,787 healthy controls) aged 15–96 years of European
ancestry. All participants provided informed consent and
each study site obtained approval from their ethics committee. In this analysis, lung cancer age-of-onset, cases
(event at diagnosis age), controls (censored at interview
age), and a covariate (smoking status) constituted the
survival outcome data that were substituted by Martingale Residuals. We randomly sampled 2/3 of the data
into a training set and 1/3 as the testing set. We applied
our novel ES-MDR method to perform an exhaustive
one-way and two-way model search. We used PLINK
as a pre-filtering step to identify uncorrelated and independent SNPs. SNPs that were in linkage disequilibrium
were removed, using a stringent correlation threshold of
0.1. After this filtering step, 108,254 SNPs remained. We
searched over all one-way and two-way interactions in
the training set to identify models consistently selected
with the largest training score determined by two-fold
cross-validation and we analysed the prediction error of
the chosen top 10 models in the testing set. In our real
data analysis, we also considered joint detection of the
two SNPs with main effects to be successful detection
of the functional interaction model. We performed a
10,000-fold permutation test to evaluate the significance
of chosen models.
To build a predictive model that combined the strength
of both one-way and two-way models, we took all the
SNPs involved in the top 1000 one-way models and all
the SNPs from the top 1000 two-way interactions models
and applied a penalized Cox regression method to filter
and select the best predictive models to evaluate genetic
factors associated with age of lung cancer onset. We
ranked the test scores from highest to lowest and picked
the top SNPs that best predicted lung cancer onset.
To construct predictive models linking SNPs to censored survival data, we used the least absolute shrinkage
and selection operator (Lasso) penalized estimation for
the Cox regression model to select top SNPs that were
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relevant to patients’ ages of lung cancer onset to create
a prediction model with a parsimonious set of SNPs that
could provide good prediction accuracy [18]. The Lasso
procedure is a popular method for variable selection
when the number of samples is significantly less than the
number of predictor variables in the prediction model
[19]. Briefly, Lasso is similar to the forward stepwise
method in that it provides coefficient shrinkage as well as
variable selection by driving nonsignificant coefficients
in a regression model to zero [19]. Therefore, Lasso is a
valuable tool to filter SNPs that are not associated with
the outcome or highly correlated with other SNPs, especially in situations when the sample size is smaller than
the number of SNP predictors.
Survival plots were generated using the Kaplan–Meier
(KM) method to visualize the differences in age of lung
cancer onset between high-risk and low-risk groups
based on top identified SNPs associated with lung cancer risk. To adjust for additional factors related to patient
survival, the Cox ph regression model included adjustment for smoking status as a covariate in the model.
To assess the performance of our model in predicting
lung cancer onset at different age intervals, we applied
time-dependent receiver operating characteristic (ROC)
curve and area under the curve (AUC) to evaluate the
predictive performance of the best models, previously
introduced by Heagerty et al. [20]. In our study, with a
given score function f(X), the time-dependent sensitivity
and specificity functions were defined as follows:




sensitivity c, t|f (X) = Pr f (X) > c|δ(t) = 1 ,




specificity c, t|f (X) = Pr f (X) ≤ c|δ(t) = 0 ,
We defined the corresponding ROC(t|f(X)) curve
for any time t as the plot of sensitivity(c, t|f(X)) versus
1—specificity(c, t|f(X)) with the cut-off point c varying.
The AUC is the area under the ROC(t|f(X)) curve, which
was denoted as AUC(t|f(X)) [18]. Here, the δ(t) is the
event indicator at time t. In this study, a larger AUC at
time t based on the score function f(X) indicated better
predictability of time-to-event at time t as measured by
sensitivity and specificity evaluated at time t.

Results
Assessing type 1 error in simulation I

In the first simulation, we determined whether the type
I error rate was close to the expected value when there
were no SNP interaction effects. Assuming a data set that
included 20 non-interacting SNPs and a total sample size
of 400, we expected the type I error rate to be 0.05.
In Fig. 1, the null distributions for the one- and twoway models followed the normal distribution quite
closely, whereas the three-way model displayed a slight
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Fig. 1 Empirical Distribution of the two-fold cross-validated testing scores. Each graph for sample sizes 200, 400, 800 and 1600 displays four curves
that represent the testing score distributions for a one-, two-, and three-way model and the standard normal distribution

Table 1 Estimated type I error rate in simulation i using
the 95th quantile of the standard normal distribution
ma = 20 na = 200
(%)

na = 400
(%)

na = 800
(%)

na = 1600 na = 3200
(%)
(%)

1-way

4.5

4.7

4.9

4.8

5.0

2-way

5.3

5.6

5.2

5.4

5.4

3-way

9.7

8.7

8.1

7.5

7.8

a

m, number of SNPs; n, sample size

right skew. Nevertheless, the upper right tail regions
almost perfectly overlapped with the upper right tail of
the normal distribution for all three interaction models. This showed that the use of the 95th quantile of the
empirical distribution as a threshold to remove false positives was suitable. This would greatly reduce the computing time by comparing testing scores with the prior
calculated empirical distribution [14]. In Table 1, we used

the 95th quantile of data sets with 400 samples to estimate the type 1 error rate. The estimated rate for type
I error was tightly distributed around 5% with a range
from 4.5 to 5.6% for the one-way and two-way models.
The estimated error rate for the three-way model was
greater with a range from 7.5 to 9.7%; however, it also
exhibited a trend towards 5% with increasing sample size.
Based on the results in Table 1, simulation I revealed that
with every two-fold increase in the sample size, there
was an average 0.6% decrease in error rate for the threeway model. As a result, we expected that the type I error
rate would converge to 5% with sample sizes greater than
approximately 12,800.
Assessing power and speed in simulation II

In the second simulation, we estimated the power of
ES-MDR with a data set that included quantitative outcome variables and a pair of functional interacting SNPs
and 18 non-interacting SNPs. We determined whether
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the power of ES-MDR was comparable to Surv-MDR
in identifying the two functional SNPs. We counted the
number of times that the functional SNP pair was correctly identified and divided that number by the total
number of data sets (500 for this simulation) to get the
estimated success rate.
Figure 2 presents a comparison of the power to identify only the two (i.e., stringent model) interacting SNPs
(SNP1 and SNP2) for ES-MDR and Surv-MDR on simulated data. Table 2 displays the percent change in power

to detect only the two functional interacting SNPs
between ES-MDR and Surv-MDR. Overall, ES-MDR
performed better than Surv-MDR for larger sample sizes.
In addition, both ES-MDR and Surv-MDR demonstrated
increasing power to detect functional SNPs with increasing heritability frequencies.
Figure 3 displays a comparison in power to identify
the two interacting SNPs (SNP1 and SNP2) plus an additional SNP (i.e., flexible model) between ES-MDR and
Surv-MDR. Table 3 shows the percent change in power

Fig. 2 Simulation II Power Comparison between ES-MDR and Surv-MDR – Stringent Model. The stringent model included two interacting SNPs (i.e.,
SNP1 and SNP2) and used n—sample sizes (e.g., 400, 800, 1600), maf—minor allele frequencies (e.g., 0.2, 0.4) and heritability statistics (e.g., 0.01, 0.02,
0.05, 0.1, 0.2, 0.3, 0.4)

Table 2 Percent change in power between ES-MDR and Surv-MDR
Heritability

0.01 (%)

0.02 (%)

0.05 (%)

0.10 (%)

0.20 (%)

0.30 (%)

0.40 (%)

− 2.5

− 0.3

na = 400
mafa
0.2

0.0

0.4

− 66.7

na = 800

− 16.7

9.1

13.6

0.0

− 15.8

− 30.0

7.7

0.0

− 0.4

− 4.0

− 6.0

5.2

mafa
0.2

100.0

16.7

15.8

16.4

0.4

38.5

4.8

9.7

3.8

1.0

− 3.9

1.1

− 0.1

− 5.0

na = 1600
mafa
0.2

433.3

1.1

6.3

28.2

7.5

3.3

0.4

24.3

15.7

5.0

8.0

− 1.7

− 0.5

a

n, sample size; maf, minor allele frequency;

b

% change calculator = ((ES-MDR − Surv-MDR)/Surv-MDR) × 100%

0.6
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Fig. 3 Simulation II Power Comparison between ES-MDR and Surv-MDR—Flexible Model. The flexible model included two interacting SNPs (i.e.,
SNP1 and SNP2) plus a third SNP3 and used n—sample sizes (e.g., 400, 800, 1600), maf—minor allele frequencies (e.g., 0.2, 0.4) and heritability
statistics (e.g., 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4)

Table 3 Percent change in power between ES-MDR and Surv-MDR
Heritability

0.01 (%)

0.02 (%)

0.05 (%)

0.10 (%)

0.20 (%)

0.30 (%)

0.40 (%)

− 34.7

− 1.2

20.6

7.0

4.2

9.0

1.4

4.6

− 0.7

na = 400
mafa
0.2

25.0

10.0

0.4

− 80.0

− 10.5

na = 800

− 4.6

11.3

mafa
0.2

16.7

17.6

25.3

21.4

7.5

0.4

16.7

− 16.7

− 10.7

7.1

11.4

na = 1600

7.5

1.0
1.4

mafa
0.2

152.6

19.4

17.9

16.6

6.6

0.3

0.0

0.4

26.7

17.2

2.6

6.6

3.4

0.6

0.0

a

n, sample size; maf, minor allele frequency;

b

% change calculator = (ES-MDR − Surv-MDR)/Surv-MDR × 100%

to detect the two interacting SNPs plus an additional
SNP. Here, we also demonstrated that ES-MDR had
greater power compared to Surv-MDR. Again, ES-MDR
performed better than Surv-MDR with larger sample
sizes.
We compared the computing time between ES-MDR
and Surv-MDR for 100 simulated data sets, for one-,
two-, and three-way interactions, and with ten-fold
cross-validation. The computing time for Surv-MDR was
734.5 min versus 2.25 min for ES-MDR, both of which

were run on 1 node in the high-performance computing cluster called Discovery with AMD 3.1 Ghz CPU
and 64 GB of memory. Discovery uses a Linux RedHat
6.7 operating system and is comprised of 160 computing
nodes (3000 + cores), 12.5 TB of memory, and is available
to the Dartmouth research community.
Application to OncoArray‑TRICL data set

The main goal was to identify SNPs with main effects
and SNP interactions that were associated with lung
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cancer susceptibility at different ages of disease onset.
Using a population-based study, we applied ES-MDR
on the OncoArray-TRICL Consortium data with 14,935
cases and 12,787 controls for lung cancer to search over
all one-way and two-way interactions to identify genetic
interactions in relation to lung cancer age-of-onset.
For this study, we included 533,631 genotyped variants
and removed SNPs in linkage disequilibrium (LD) > 0.1
(n = 108,254 SNPs).
Table 4 lists the top 10 one-way test results generated
by ES-MDR and cross-validation. Using ES-MDR, highly
significant SNPs were identified in association with lung
cancer age-of-onset. Table 5 displays the top 10 two-way
interactions identified by ES-MDR that were associated
with lung cancer age-of-onset. Due to the observed inflation of the type 1 error rate for 3-way interactions in the
simulation study, a 3-way interaction was not evaluated
in the OncoArray-TRICL data analysis. For Table 6, we
combined SNPs from the top 1000 one-way loci and the
top 1000 two-way interactions, ranked the SNP scores
from highest to lowest, and applied the Lasso Cox regression method to filter and select the best genetic factors
that predicted age of lung cancer onset. Table 6 exhibits the top 10 significant SNPs selected by Lasso Cox
regression. To visualize the difference in age of lung
cancer onset between the high risk and low risk groups,
Fig. 4 illustrates the contrast using the KM) survival
curve. KM curves for top one-way SNPs in the intronic
region of TULP1, FKBP5 (rs6906359), in-between genes
GTF2IP1, PMS2P5 (rs149743903), and in the deletion of a noncoding region of BRCA1 (rs749410065)
(NC_000017.10:g.41196821delT per Human Genome
Variation Society nomenclature), and for a top twoway interacting SNPs in gene regions of BRCA1
(rs749410065) and CBR1, LOC100133286 (rs151043730)

displayed a clear separation of curves between the highand low-risk groups. This demonstrated the efficacy of
ES-MDR using Martingale Residuals to differentiate
high risk and low risk groups based on genotype variation when evaluating lung cancer age-of-onset. We continued our analysis with a comparison of smoking only
and smoking plus SNP models to determine the best
performance in predicting lung cancer onset at different
ages. We used a common graphical plot called the area
under the receiver operating characteristic (ROC) curve,
also known as AUC, to measure the performance of our
models to discriminate the best parameters at predicting
lung cancer onset at different ages based on accuracy. In
Fig. 5, the x-axis corresponds to the age of lung cancer
onset, starting from 15 to > 80 years, and the y-axis indicates the AUC, ranging from 0.4 to 1. We examined the
predictive performance of 7 different models with various tuning parameters identified from Cox Lasso regression, such as smoking only and smoking plus 2 SNPs, 4
SNPs, 13 SNPs, 19 SNPs, 29 SNPs, and 183 SNPs. This
figure shows the average of the estimated AUCs over the
OncoArray-TRICL data using the predictive scores from
the independent left-out test data set. The plot displays
good predictive performances of models generated using
ES-MDR. The AUC for models with more SNPs lies
between 0.6 and 0.7 and continues to increase at later
ages of onset. There is a noticeable decrease in AUC for
ages 40 and below. This could be due to the limited number of lung cancer cases identified for individuals below
the age of 40, which indicated that the models might
not be appropriate to predict lung cancer diagnoses at
40 years and younger. The AUC of both smoking only and
smoking with SNPs increased with age from age 40 and
older. However, the AUC, depending on the number of
SNPs in the models, differed by age. The model with the

Table 4 Top-one-way models identified by ES-MDR in OncoArray-TRICL data
Nearest Gene(s)

Chra SNP (GRCh37/
hg19)

Position (bpa) Gene Region Alleles
GRCh37/hg19
(Major/
Minor)

MAFa
(1000
Genomes)

Log-rank
Test
score

OncoArraygenotyped
(HRa)

Permutation
P value

LINC00708,
LOC105755953

10

rs12358150

8735744

Intergenic

C/T

0.26

340.90

20.51

< 0.0001

GTF2IP1, PMS2P5

7

rs149743903

74711828

Intergenic

T/C

NAa

295.80

6.39

< 0.0001

PPP2R2B, STK32A

5

rs76601208

146581977

Intron

C/T

0.002

180.30

22.83

< 0.0001

KLF5, LINC00392

13

rs138428539

73736950

Intergenic

T/C,G

0.01

145.10

6.46

< 0.0001

TULP1, FKBP5

6

rs6906359

35528378

Intron

C/T

0.10

135.90

5.76

< 0.0001
< 0.0001

UTP23, RAD21

8

rs10105870

117807762

Intergenic

G/A

0.15

113.00

27.64

VPS8

3

rs112047443

184701960

Intron

A/T

NAa

93.30

19.57

< 0.0001

BRCA1

17

rs749410065

41196821

delTa

-/T

NAa

62.20

1.24

< 0.0001

ATR

3

rs529613417

142285472

Intron

A/T

0.001

57.00

5.48

< 0.0001

B3GNT2, TMEM17

2

rs11526118

62647317

Intron

G/A

0.16

46.00

23.01

0.0033

a

Chr, chromosome; bp, base pair; MA, minor allele frequency; detT, NC_000017.10:g.41196821delT; NA, not available; HR, hazard ratio

A/C
–/T

Intron

Intron, 3′
UTRa

Intergenic

Intron

Intergenic

Intergenic

delTa

rs16870005

rs7535067

rs57092860

rs7732411

rs182398206

rs6698924

rs749410065

C6orf10

C1orf21,
LOC107985236

PSMB9,
LOC100294145

CTNND2

TRAM2-AS1,
LOC730101

MIR4417,
MIR4689

BRCA1

a

G/A

A/G

T/C

T/C,G

C/A,T

0.002

NAa

0.02

0.01

0.08

0.01

0.19

0.01

NAa

NAa

MAFa
(1000
Genomes)

BRCA1

TFAP2C, BMP7

BRCA1

BRCA1

BRCA1

BRCA1

BRCA1

BRCA1

NAPG

CBR1,
LOC100133286

Gene(s) 2

rs749410065

rs186132350

rs749410065

rs749410065

rs749410065

rs749410065

rs749410065

rs749410065

rs3865365

rs151043730

SNP 2
(GRCh37/
hg19)

–/T
–/T
–/T
–/T
–/T
–/T

delTa
a

delTa
delTa
delTa
delTa

0.01
NAa
–/T

Intergenic T/A

NAa

NAa

NAa

NAa

NAa

NAa

0.06

0.001

13.28

13.29

13.29

13.30

13.32

13.37

13.39

13.42

13.43

13.77

MAF (1000 ES-MDR
Genomes) Test
Score

delTa

delT

G/A

G/A

Alleles
(Major/
Minor)

near 5′
end of
genes

missense,
ncRNAa

Gene
Region 2

UTR, untranslated region; delT , NC_000017.10:g.41196821delT; ncRNA, noncoding transcript variant; HR, hazard ratio; NA, not available

a

Intergenic

–/T

delTa

rs749410065

BRCA1

HRAT92, PRKAR1B rs142263110

–/T

delTa

rs749410065

BRCA1

C/T

Alleles
(Major/
Minor)

Gene
Region 1

SNP 1
(GRCh37/
hg19)

Gene(s) 1

Table 5 Top two-way models identified by ES-MDR in OncoArray-TRICL data

1.25

1.25

1.25

1.25

1.25

1.25

1.24

1.25

1.23

1.24

OncoArraygenotyped
(HRa)

69.36

69.79

68.74

70.95

67.53

67.82

61.92

67.66

61.74

65.74

Log-rank
test
statistic

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

Permutation
P value
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Table 6 Top SNPs selected by cox lasso regression in OncoArray-TRICL data
Nearest Gene(s)

Chra SNP (GRCh37/
hg19)

Position (bpa)
(GRCh37/
hg19)

Gene region Alleles
(Major/
Minor)

MAFa
(1000
Genomes)

BRCA1

17

rs749410065

41196821

delTa

–/T

NAa

62.20

1.24

< 0.0001

GTF2IP1, PMS2P5

7

rs149743903

35528378

Intergenic

C/G

NAa

295.80

6.39

< 0.0001

LOC102467079,
TOX3

16

rs117142114

52328666

Intergenic

T/C

0.02

31.00

1.29

< 0.0001

HYKK

15

rs9788721

78802869

Intron

C/T

0.31

86.30

1.41

< 0.0001

MIR3925, PANDAR

6

rs7753169

36614326

Intergenic

A/C

0.36

27.90

1.15

< 0.0001

CHRNA5

15

rs16969968

78882925

missense

G/A

0.15

86.80

1.41

< 0.0001

KLF5, LINC00392

13

rs138428539

73736950

Intergenic

T/C,G

0.01

145.10

6.46

< 0.0001

TULP1, FKBP5

6

rs6906359

35528378

Intron

C/T

0.10

135.90

5.76

< 0.0001

CHRNA5

15

rs951266

78878541

Intron

G/A

0.16

88.50

1.41

< 0.0001

FAM114A1

4

rs1873195

38891173

Intron

C/T

0.20

8.90

0.87

0.0119

a

Test score OncoArraygenotyped
(HRa)

Permutation
P value

Chr, chromosome; NA, not available; bp, base pair; delTa = NC_000017.10:g.41196821delT; MAF, minor allele frequency; HR, hazard ratio

largest number of SNPs plus smoking performed the best
at AUC 0.68 between ages 40 and 80 of onset compared
to the smoking-only model with an AUC of 0.55. There
was a noticeable trend where incremental additions of
SNPs in the model increased the AUC for age-of-onset
between 40 and 80 + . On the other hand, the AUC for
smoking-only and smoking plus fewer SNP models (e.g.,
2 and 4) displayed the opposite trend where it increased
around 90 + years of age.

Discussion
In this study, we present a novel algorithm to identify
genetic interactions associated with the age-of-onset for
lung cancer. We demonstrated in two simulation studies
that our ES-MDR method was properly controlled for at
the 5% type I error rate under the null distribution and
improved power to detect causal SNPs. We identified
new loci that were biologically plausible for lung cancer
onset using the large OncoArray-TRICL data with 27,722
individuals. There are two unique contributions from this
study. First, we offer a more computationally efficient
algorithm, ES-MDR, a method that analyses survival
data by using Martingale residuals in place of survival
outcome data. Second, ES-MDR includes the ability to
adjust for covariates, such as smoking status, a necessary
step to control for confounding factors, whereas existing
methods, used for survival analysis such as Surv-MDR,
are unable to provide.
Using the MDR method to reduce the size of multiple
dimensions to a single dimension to identify multi-locus
genetic interactions in high-dimensional genomic data
sets has been a well-established approach. Richie et al.
(2001) first introduced MDR, a non-parametric (i.e., no
parameters are estimated) and genetic model-free (i.e.,
no genetic model is assumed) model, that condensed

multiple genetic loci into a single variable in order to categorize genotypes into two groups [7]. The goal was to
group genotypes into high-risk and low-risk categories
associated with and without disease outcomes, respectively. However, MDR was restricted by its inability to
analyze different outcome variables other than binary
variables and it did not allow for the adjustment of confounding factors that was critical in preventing false
association analyses. Therefore, an extension of the traditional MDR method was developed to analyze censored
survival data, called Survival MDR or Surv-MDR.
Like the original MDR algorithm, Surv-MDR is a nonparametric and genetic model-free method proposed by
Gui et al. (2011), and it was developed to allow for the
analysis of time-to-event data, such as patient survival
time or time to disease relapse [13]. Surv-MDR used the
log-rank test statistic to compare survival times between
samples with and without the multi-locus risk genotype
combination and classified them into high and low risk
groups [13]. Surv-MDR also used cross-validation to
identify the optimal set of K SNPs and overall best model.
While Surv-MDR was successful in identifying SNP
interactions associated with time-to-event outcomes, it
was more computationally demanding than MDR and the
inability to adjust for covariates persisted. Consequently,
the MDR method was optimized further to develop the
Quantitative MDR (QMDR) method to address the slowto-compute algorithm challenge [14].
QMDR optimized the MDR algorithm by offering a
computationally efficient way to analyze quantitative or
continuous trait outcomes. QMDR compared the mean
value of each multi-locus genotype to the overall mean
and labeled each genotype combination as “high-risk”
or “low-risk”. Cross-validation was also implemented in
QMDR to identify the optimal set of K SNPs and overall
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GTF2IP1, PMS2P5 (rs149743903)

Log−rank test statistic is 135.9

0.8
0.6
0.4

Log−rank test statistic is 295.8
p−value < 0.0001
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BRCA1 (rs749410065) & CBR1, LOC100133286 (rs151043730)
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0.8
0.6

Log−rank test statistic is 65.7
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0.0
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Age of Onset (Years)

Fig. 4 Differences between High Risk (red curve) and Low Risk (blue curve) groups in relation to SNPs. Kaplan–Meier plots displays the difference
between individuals categorized in High Risk vs. Low Risk groups by genetic variation in top one-way SNPs identified from the testing set, TULP1/
FKBP5 (rs6906359), GTF2IP1/PMS2P5 (rs149743903), and BRCA1 (rs749410065) (NC_000017.10:g.41196821delT), and in a top two-way interacting
SNPs from the testing set, BRCA1 (rs749410065) (NC_000017.10:g.41196821delT) & CBR1, LOC100133286 (rs151043730)

best model. For each K-way interaction, the steps used
for a k-fold cross-validation were similar to the SurvMDR method except for the step to identify the best
K-way interaction. In this case, the largest T-test statistic was used instead of the square of the log-rank statistic when identifying the best interaction model. Inspired
by the computational capabilities of QMDR to analyze
quantitative outcomes associated with genetic variations,
we leveraged this method’s straightforward computing
efficiency to evaluate survival outcome data for time-toevent analysis.

Our approach transformed survival data (e.g., time and
event status) into a single variable, Martingale Residuals, to use as a surrogate for time-to-disease and disease
status, with application of QMDR for rapid processing
of genotype combinations into high and low risk groups.
We were able to identify thousands of significant one-way
and two-way models using ES-MDR and cross-validation
when applied to the lung cancer OncoArray-TRICL data
set. We were unable to compare the results of ES-MDR
and Surv-MDR, both because Surv-MDR would have
taken an extensive amount of time (e.g., greater than
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Fig. 5 Plots of Area under the curve (AUC). Each line corresponds to a model. Models were smoking only and smoking plus 2 to 183 SNPs. Here we
compared the AUCs between the smoking only model and smoking plus SNPs models for predicting lung cancer age-of-onset ranging from 20
to < 100 years. The number of individuals diagnosed with lung cancer at < 40 years, 40 to < 60 years, 60 to < 80 years, and 80 to < 100 years is shown
below the figure

4 months) to conduct a genome-wide genetic interaction analysis using the large OncoArray-TRICL data set,
and because the current Surv-MDR algorithm would
not allow for adjustment of confounding factors such as
smoking status.
When searching for SNP interactions using real data,
we chose a two-fold cross-validation instead of a ten-fold
cross-validation to evaluate the optimal one-way and
two-way interaction models as described previously [14].
From the central limit theorem, assuming a sufficiently
large sample size (n > 50) from a population with a finite
level of variance, the mean of all samples from the same
population would be approximately equal to the mean of
the population. Therefore, we expected the testing scores
with 400 samples from our simulation study to follow a
standard normal distribution. However, Gui et al. (2013)
displayed a slight right skew with a standard deviation of
1.6 in their empirical distributions that was due to extra
variation introduced by overlapping training sets in their
ten-fold cross-validation method [14, 21]. Furthermore,
two-fold cross-validation had been advocated to perform
hypothesis testing where the training folds were mutually independent with no overlap [21]. Consequently,

we evaluated the optimal one-way and two-way interaction models and the overall best model using two-fold
cross-validation.
We explored prediction models that included SNPs
that could be used to forecast lung cancer onset. Figure 5
lays out the AUC estimates for each model. The AUC
peaked around age-of-onset less than 30 and greater than
90 years old. This may be due to the limited number of
lung cancer cases (e.g., less than 10 cases) at younger and
older ages. In general, based on AUC averages, age of lung
cancer onset was strongly influenced by genetic variants,
with increasing numbers of SNPs contributing to better
AUC estimates. The plateauing of AUC averages for the
40–80 years old range revealed good estimates for age of
onset for all models, which was likely due to the larger
sample size for evaluation. Another plausible explanation
for the high AUC for early and late age of onset was the
likelihood that those cases contained the same combinations of risk SNPs in the models. The identified top SNPs
with high AUC for age of onset were not only associated
with early lung cancer cases, but they potentially could
also contribute to late age of onset cases. The 2 SNP and
4 SNP models had strong associations with lung cancer
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cases and therefore, were responsible for high AUC averages for early and late age of onset of lung cancer. For the
smoking only model, it played less of a role for early lung
cancer onset because the adverse effects from smoking
could require more time to develop. Over time the effects
from smoking could be the main driver for late age lung
cancer cases, which could explain why genetic factors
do not seem to greatly effect cancer onset in later years.
This interpretation could make biological sense since
the effect of smoking over a longer time period could
have compounding effects on cancer development. Conversely, cancer development due to genetics might appear
at earlier rather than later years.
Limitations

While our novel ES-MDR overcame some of the limitations described in previous methods used to evaluate
genetic interactions, it was not without some of its own
disadvantages. When analyzing survival data, the method
did not directly evaluate survival variables such as time
and event status. As a result, when using Martingale
Residuals instead of specific survival outcomes data, we
might be missing some important information that was
needed to identify associations between SNP interactions and survival outcomes. Our QQ plot analysis from
real data indicated a strong departure from the null distribution which indicated that there might exist a systematic bias. This result could be due to a combination
of the large sample size and continuous outcome. As a
result, we used permutation tests to evaluate the results
from the OncoArray-TRICL data set. Another limitation came from over parameterizing our models, resulting in many multifactor cells with missing data [7]. This
did not affect the classification of genotype combinations
or identifying cross-validation consistency of the model,
however, it could affect our estimation of the prediction
error [7]. Future studies would need to address this limitation. Next, we applied our ES-MDR method to analyze
survival outcomes using case–control studies, where
estimating the age-specific incidence (e.g., age-of-onset)
was not typically designed for case–control studies. On
the other hand, cohort studies, which are designed for
survival analyses, are expensive and require a great deal
of follow-up time to obtain age-of-onset information.
This could be one of the barriers in analyzing survival
outcomes for large cohort studies; it could require a lot
of time and resources to amass an extensive amount of
data. In our study, we were able to analyze and identify
potential genetic markers that predicted lung cancer risk
using a large lung cancer GWAS consortium data, which
could be followed up with further investigations for biological and functional significance. Due to fewer available
observations of lung cancer age-of-onset among younger
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individuals, we were limited in our ability to predict
lung cancer onset for individuals 40 years and younger.
With continuous efforts in recruiting participants in the
OncoArray-TRICL Consortium, we might find more
cases among the early onset population to better predict lung cancer risk in the future. Finally, there were no
available validation data to replicate our top SNP findings
because these SNPs were not likely genotyped in other
GWAS data sets. Currently, there are ongoing efforts to
collect external data that will include genotyping of our
top SNP findings for replication.
Future studies

ES-MDR is a powerful alternative to Surv-MDR for
identifying interactions, especially at the genome-wide
scale. We demonstrated its ability to identify high-order
genetic interactions in simulated and real data sets.
Although ES-MDR addresses previous limitations of
Surv-MDR and other MDR-like methods, there are ways
in which this method can be improved. While ES-MDR
had greatly improved computing efficiency, genome-wide
scans for interactions will still require massive computing
resources, especially to analyze higher-order interactions.
It will be necessary to optimize the selection of SNPs in
predictive models, for example, by selecting genes known
to participate in biological and metabolic pathways [22].
This can improve the predictive ability of ES-MDR for
two-, three, and multi-way interactions in a pathway
analysis. Second, a future study may entail introducing
variance back to Martingale Residuals by way of weighting each residual based on the time-to-event data. This
can greatly improve our power for model selection without removing the efficiency of the algorithm.

Conclusions
In summary, the ES-MDR method provides a way to analyze high-order interactions at the genome-wide scale to
advance studies of genetic interactions. We developed
a new method that efficiently captures non-linear and
high-order interactions for time-to-event analysis.In general, ES-MDR has improved power performance relative
to Surv-MDR using simulated data. Based on the noticeable trends, we are confident that with bigger sample sizes,
ES-MDR will continue to significantly gain in power to
detect functional interacting SNPs without inflating the
type I error rate. Providing new and improved methods
to analyze epistasis or gene interactions may offer new
opportunities to not only explain the missing heritability
for complex disease risk, but can also potentially detect
new genetic determinants that is important for clinical
utility such as disease diagnosis and prognosis.
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